EA019804B1 - Полимеризованная мицелла - Google Patents
Полимеризованная мицелла Download PDFInfo
- Publication number
- EA019804B1 EA019804B1 EA201001692A EA201001692A EA019804B1 EA 019804 B1 EA019804 B1 EA 019804B1 EA 201001692 A EA201001692 A EA 201001692A EA 201001692 A EA201001692 A EA 201001692A EA 019804 B1 EA019804 B1 EA 019804B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- polymerized
- bond
- amphiphilic molecules
- molecules
- micelles
- Prior art date
Links
- 239000000693 micelle Substances 0.000 title claims abstract description 139
- 230000007935 neutral effect Effects 0.000 claims abstract description 6
- 150000004676 glycans Chemical class 0.000 claims abstract description 5
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 5
- 239000005017 polysaccharide Substances 0.000 claims abstract description 5
- 230000002209 hydrophobic effect Effects 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 17
- 238000006116 polymerization reaction Methods 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 11
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 10
- 235000019152 folic acid Nutrition 0.000 claims description 10
- 239000011724 folic acid Substances 0.000 claims description 10
- 229960000304 folic acid Drugs 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- -1 COOH radical Chemical class 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000010526 radical polymerization reaction Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 101000913968 Ipomoea purpurea Chalcone synthase C Proteins 0.000 claims description 3
- 101000907988 Petunia hybrida Chalcone-flavanone isomerase C Proteins 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 125000003473 lipid group Chemical group 0.000 abstract 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 13
- 241000700159 Rattus Species 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000010348 incorporation Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229930012538 Paclitaxel Natural products 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229960001592 paclitaxel Drugs 0.000 description 6
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000007306 functionalization reaction Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- LLCSWKVOHICRDD-UHFFFAOYSA-N buta-1,3-diyne Chemical group C#CC#C LLCSWKVOHICRDD-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 238000002189 fluorescence spectrum Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- RXCMFQDTWCCLBL-UHFFFAOYSA-N 4-amino-3-hydroxynaphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(N)=C(O)C=C(S(O)(=O)=O)C2=C1 RXCMFQDTWCCLBL-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000005660 hydrophilic surface Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000003760 magnetic stirring Methods 0.000 description 3
- 239000002063 nanoring Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- RXCMFQDTWCCLBL-UHFFFAOYSA-M 4-amino-3-hydroxynaphthalene-1-sulfonate Chemical compound C1=CC=C2C(N)=C(O)C=C(S([O-])(=O)=O)C2=C1 RXCMFQDTWCCLBL-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000002071 nanotube Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229920000359 diblock copolymer Polymers 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical class OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- ZPUDRBWHCWYMQS-UHFFFAOYSA-N pentacosa-10,12-diynoic acid Chemical class CCCCCCCCCCCCC#CC#CCCCCCCCCC(O)=O ZPUDRBWHCWYMQS-UHFFFAOYSA-N 0.000 description 1
- DZLWMPMXBUHMQV-UHFFFAOYSA-N pentacosa-2,4-diynoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCC#CC#CC(O)=O DZLWMPMXBUHMQV-UHFFFAOYSA-N 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000000596 photon cross correlation spectroscopy Methods 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000015 polydiacetylene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Developing Agents For Electrophotography (AREA)
- Graft Or Block Polymers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0802390A FR2930444B1 (fr) | 2008-04-29 | 2008-04-29 | Micelles polymerisees |
| PCT/FR2009/000493 WO2009133325A2 (fr) | 2008-04-29 | 2009-04-28 | Micelles polymerisees |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201001692A1 EA201001692A1 (ru) | 2011-08-30 |
| EA019804B1 true EA019804B1 (ru) | 2014-06-30 |
Family
ID=40019326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201001692A EA019804B1 (ru) | 2008-04-29 | 2009-04-28 | Полимеризованная мицелла |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8663660B2 (https=) |
| EP (1) | EP2282727B1 (https=) |
| JP (1) | JP2011518868A (https=) |
| AT (1) | ATE534376T1 (https=) |
| AU (1) | AU2009241887B2 (https=) |
| CA (1) | CA2722050C (https=) |
| CY (1) | CY1112266T1 (https=) |
| DK (1) | DK2282727T3 (https=) |
| EA (1) | EA019804B1 (https=) |
| ES (1) | ES2378283T3 (https=) |
| FR (1) | FR2930444B1 (https=) |
| HR (1) | HRP20120150T1 (https=) |
| ME (1) | ME01991B (https=) |
| PL (1) | PL2282727T3 (https=) |
| PT (1) | PT2282727E (https=) |
| RS (1) | RS52170B (https=) |
| SI (1) | SI2282727T1 (https=) |
| WO (1) | WO2009133325A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130039864A1 (en) * | 2010-04-23 | 2013-02-14 | Francois Ravenelle | Non-Intravenous Dosage Form Comprising Solid Formulation of Liquid Biologically Active Agent and Uses Thereof |
| EP2425817A1 (en) | 2010-08-09 | 2012-03-07 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Polymerized micelles for diagnosis |
| CN108586291A (zh) * | 2018-01-02 | 2018-09-28 | 成都傲飞生物化学品有限责任公司 | 一种n，n-双（羧甲基）-l-赖氨酸的生产工艺 |
| CN110893172B (zh) * | 2019-12-04 | 2022-07-08 | 四川省人民医院 | 一种榄香烯聚合物胶束制剂及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020064513A1 (en) * | 2000-09-18 | 2002-05-30 | Amarnath Maitra | Sustained release and long residing ophthalmic formulation and the process of preparing the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030133972A1 (en) * | 2000-10-11 | 2003-07-17 | Targesome, Inc. | Targeted multivalent macromolecules |
| FR2853657B1 (fr) | 2003-04-10 | 2005-06-24 | Centre Nat Rech Scient | Macromolecules auto assemblees et photopolymerisees autour de nanotubes de carbone, un procede pour leur preparation, et leurs applications |
| US7316816B2 (en) * | 2004-06-10 | 2008-01-08 | Agency For Science Technology And Research | Temperature and pH sensitive copolymers |
-
2008
- 2008-04-29 FR FR0802390A patent/FR2930444B1/fr not_active Expired - Fee Related
-
2009
- 2009-04-28 AT AT09738359T patent/ATE534376T1/de active
- 2009-04-28 RS RS20120040A patent/RS52170B/sr unknown
- 2009-04-28 WO PCT/FR2009/000493 patent/WO2009133325A2/fr not_active Ceased
- 2009-04-28 EA EA201001692A patent/EA019804B1/ru not_active IP Right Cessation
- 2009-04-28 DK DK09738359.0T patent/DK2282727T3/da active
- 2009-04-28 SI SI200930177T patent/SI2282727T1/sl unknown
- 2009-04-28 CA CA2722050A patent/CA2722050C/fr not_active Expired - Fee Related
- 2009-04-28 AU AU2009241887A patent/AU2009241887B2/en not_active Ceased
- 2009-04-28 JP JP2011506742A patent/JP2011518868A/ja active Pending
- 2009-04-28 ES ES09738359T patent/ES2378283T3/es active Active
- 2009-04-28 ME MEP-2012-158A patent/ME01991B/me unknown
- 2009-04-28 HR HR20120150T patent/HRP20120150T1/hr unknown
- 2009-04-28 PT PT09738359T patent/PT2282727E/pt unknown
- 2009-04-28 EP EP09738359A patent/EP2282727B1/fr active Active
- 2009-04-28 PL PL09738359T patent/PL2282727T3/pl unknown
- 2009-04-28 US US12/736,627 patent/US8663660B2/en not_active Expired - Fee Related
-
2012
- 2012-01-25 CY CY20121100088T patent/CY1112266T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020064513A1 (en) * | 2000-09-18 | 2002-05-30 | Amarnath Maitra | Sustained release and long residing ophthalmic formulation and the process of preparing the same |
Non-Patent Citations (1)
| Title |
|---|
| GOTO ET AL.: "Micellar Behaviour of Sugar-Carrying Polystyrene in Aqueous Solution". MACROMOL. CHEM. PHYS., vol. 202, no. 7, 2001, pages 1161-1165, XP002505668. Weinheim, figure 1, page 1162, paragraph 1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| SI2282727T1 (sl) | 2012-03-30 |
| JP2011518868A (ja) | 2011-06-30 |
| ME01991B (me) | 2012-08-31 |
| DK2282727T3 (da) | 2012-03-05 |
| US8663660B2 (en) | 2014-03-04 |
| CA2722050C (fr) | 2013-11-19 |
| FR2930444B1 (fr) | 2010-06-04 |
| EA201001692A1 (ru) | 2011-08-30 |
| AU2009241887B2 (en) | 2013-07-04 |
| HRP20120150T1 (hr) | 2012-03-31 |
| ATE534376T1 (de) | 2011-12-15 |
| ES2378283T3 (es) | 2012-04-10 |
| US20110105516A1 (en) | 2011-05-05 |
| CA2722050A1 (fr) | 2009-11-05 |
| EP2282727A2 (fr) | 2011-02-16 |
| EP2282727B1 (fr) | 2011-11-23 |
| CY1112266T1 (el) | 2016-10-05 |
| WO2009133325A2 (fr) | 2009-11-05 |
| RS52170B (sr) | 2012-08-31 |
| FR2930444A1 (fr) | 2009-10-30 |
| WO2009133325A3 (fr) | 2010-01-28 |
| PL2282727T3 (pl) | 2012-04-30 |
| AU2009241887A1 (en) | 2009-11-05 |
| PT2282727E (pt) | 2012-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liao et al. | Dual pH-responsive-charge-reversal micelle platform for enhanced anticancer therapy | |
| JP5737705B2 (ja) | 高分子化環状ニトロキシドラジカル化合物およびその使用 | |
| US9872926B2 (en) | Multicolored pH-activatable fluorescence nanoplatform | |
| JP5848332B2 (ja) | 光学造影および療法のタンデムのための官能性架橋型ナノ構造物 | |
| EP2774625B1 (en) | Polymer-type fluorescent molecule probe | |
| JP2011503067A (ja) | 生物学的適用のためのフォトニックシェルコアが架橋し、官能化されたナノ構造 | |
| CN113827567B (zh) | 载小分子药聚合物囊泡在制备治疗急性淋系白血病药物中的应用 | |
| JP2017526753A (ja) | ｐＨ応答性ポリマーのライブラリー及びそのナノプローブ | |
| Buwalda et al. | Reversibly core-crosslinked PEG-P (HPMA) micelles: Platinum coordination chemistry for competitive-ligand-regulated drug delivery | |
| CN111973556B (zh) | 载小分子药聚合物囊泡及其制备方法与应用 | |
| CN103476801B (zh) | 用于药物递送的纤维素基纳米粒子 | |
| EA019804B1 (ru) | Полимеризованная мицелла | |
| AU2014332069A1 (en) | Self-assembled brush block copolymer-nanoparticles for drug delivery | |
| CN104116709A (zh) | 靶向肿瘤的抗肿瘤耐药的pH敏感聚合物胶束组合物 | |
| CN111643678B (zh) | 基于含巯基的两性离子多肽修饰的阿霉素衍生物、纳米胶束及其制备方法 | |
| US20150065442A1 (en) | Reducible self-assembled micelle drug delivery systems | |
| Guan et al. | Design, synthesis, and characterization of glycyrrhetinic acid-mediated multifunctional liver-targeting polymeric carrier materials | |
| JP2023507617A (ja) | 脳腫瘍を治療するための架橋ナノセラノスティクスにおけるシーケンシャルターゲティング | |
| JP7100457B2 (ja) | ブロックコポリマー、ミセル組成物、及び医薬組成物 | |
| CN114380991A (zh) | 一种聚合物-脂质偶联物及其制备方法和应用 | |
| HK40116040A (zh) | 无定形光敏粒子、其制备方法及其使用方法 | |
| CN116284617A (zh) | 一种刺激响应性的线性-树枝状嵌段聚合物及其制药用途 | |
| Zhang | RATIONAL DESIGN OF NANOCARRIERS WITH ENHANCED CARRIER-DRUG INTERACTION FOR IMPROVED CANCER THERAPY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |